Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi President Emphases Overseas Expansion And To Increase R&D Expenses

This article was originally published in PharmAsia News

Executive Summary

Shionogi President Isao Teshirogi emphasized the importance of overseas expansion for the company at a May 12 press briefing to announce results for the fiscal year. Teshirogi noted the royalty Shionogi received on cholesterol drug Crestor, which the company licensed to AstraZeneca, has reached ¥29.8 billion in 2007, and estimated to reach ¥38.8 billion and ¥60 billion in 2008 and 2009. To expand in the global market, Shionogi plans to focus on attracting talents and alliances, and increase R&D spending from 2007's ¥40.2 billion to ¥50 billion over the next two years. (Click here for more - Japanese language)
Advertisement

Related Content

Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
Advertisement
UsernamePublicRestriction

Register

SC068498

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel